{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,16]],"date-time":"2025-10-16T00:37:08Z","timestamp":1760575028076,"version":"build-2065373602"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T00:00:00Z","timestamp":1756944000000},"content-version":"vor","delay-in-days":3,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Alnylam Pharmaceuticals Inc."},{"name":"Universit\u00e4tsklinikum Schleswig-Holstein - Campus Kiel"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2025,9]]},"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Hereditary transthyretin (ATTRv) amyloidosis is a progressive multisystem disorder, mainly characterized by cardiac dysfunction and polyneuropathy. Due to its rarity and heterogeneous presentation, diagnosis is often delayed, which has a direct impact on the initiation of treatment and, therefore, span and quality of life. To facilitate early disease recognition, we aimed to develop and validate a new screening tool for early identification of ATTRv amyloidosis with polyneuropathy (AmyloScan<jats:sup>\u00ae<\/jats:sup>). Potential disease characteristics were identified via literature screening, interviews and detailed examination of ATTRv amyloidosis patients (<jats:italic>n<\/jats:italic>\u2009=\u200910) and controls (CIDP: chronic inflammatory demyelinating polyneuropathy, <jats:italic>n<\/jats:italic>\u2009=\u200915; diabetic polyneuropathy, <jats:italic>n<\/jats:italic>\u2009=\u200915) using validated questionnaires, and autonomic and sensory testing. The preliminary AmyloScan\u00ae was developed and validated in patients with polyneuropathy caused by ATTRv amyloidosis (<jats:italic>n<\/jats:italic>\u2009=\u200921), CIDP (<jats:italic>n<\/jats:italic>\u2009=\u200919), or others (<jats:italic>n<\/jats:italic>\u2009=\u200943). By sensitivity and discriminant analyses, we determined the most characteristic item combinations for ATTRv amyloidosis. Cut-off values were defined by Receiver Operator Curves. The final AmyloScan\u00ae includes 12 questions and two sensory bedside tests. All items require simple yes\/no answers, resulting in a total score of 0\u201314 points and two cut-off values: A value of\u2009\u2265\u20094 indicates an increased chance (sensitivity: 95.2%, specificity: 72.6%); a value of\u2009\u2265\u20096 indicates a high chance of ATTRv polyneuropathy (sensitivity: 81.0%, specificity: 93.5%). The AmyloScan<jats:sup>\u00ae<\/jats:sup> is a simple time- and cost-efficient screening tool with a high discriminative value. Regular use in clinical practice might enable an earlier diagnosis with impact on treatment considerations and quality of life.<\/jats:p>","DOI":"10.1007\/s00415-025-13338-z","type":"journal-article","created":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T02:41:54Z","timestamp":1756953714000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["A new screening tool for early recognition of ATTRv polyneuropathy in clinical practice: AmyloScan\u00ae"],"prefix":"10.1007","volume":"272","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5787-6562","authenticated-orcid":false,"given":"Juliane","family":"Sachau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lena","family":"Rhode","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maike F.","family":"Dohrn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jan","family":"Vollert","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Rehm","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manon","family":"Sendel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrin","family":"Hahn","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Timon","family":"Hansen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"Gingele","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Skripuletz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Klarissa","family":"St\u00fcrner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Enax-Krumova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ralf","family":"Baron","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,9,4]]},"reference":[{"key":"13338_CR1","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1038\/s41582-019-0210-4","volume":"15","author":"D Adams","year":"2019","unstructured":"Adams D, Koike H, Slama M, Coelho T (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease. Nat Rev Neurol 15:387\u2013404. https:\/\/doi.org\/10.1038\/s41582-019-0210-4","journal-title":"Nat Rev Neurol"},{"key":"13338_CR2","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1212\/WNL.0000000000001160","volume":"84","author":"NA Visser","year":"2015","unstructured":"Visser NA, Notermans NC, Linssen RSN et al (2015) Incidence of polyneuropathy in Utrecht, the Netherlands. Neurology 84:259\u2013264. https:\/\/doi.org\/10.1212\/WNL.0000000000001160","journal-title":"Neurology"},{"key":"13338_CR3","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/mus.26034","volume":"57","author":"HH Schmidt","year":"2018","unstructured":"Schmidt HH, Waddington-Cruz M, Botteman MF et al (2018) Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 57:829\u2013837. https:\/\/doi.org\/10.1002\/mus.26034","journal-title":"Muscle Nerve"},{"key":"13338_CR4","doi-asserted-by":"publisher","first-page":"901","DOI":"10.1002\/ana.24519","volume":"78","author":"L-L Mariani","year":"2015","unstructured":"Mariani L-L, Lozeron P, Th\u00e9audin M et al (2015) Genotype-phenotype correlation and course of transthyretin familial amyloid polyneuropathies in France. Ann Neurol 78:901\u2013916. https:\/\/doi.org\/10.1002\/ana.24519","journal-title":"Ann Neurol"},{"key":"13338_CR5","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1136\/jnnp-2011-301299","volume":"83","author":"H Koike","year":"2012","unstructured":"Koike H, Tanaka F, Hashimoto R et al (2012) Natural history of transthyretin Val30Met familial amyloid polyneuropathy: analysis of late-onset cases from non-endemic areas. J Neurol Neurosurg Psychiatry 83:152\u2013158. https:\/\/doi.org\/10.1136\/jnnp-2011-301299","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13338_CR6","doi-asserted-by":"publisher","first-page":"785","DOI":"10.1212\/WNL.0b013e3182661eb1","volume":"79","author":"T Coelho","year":"2012","unstructured":"Coelho T, Maia LF, Martins da Silva A et al (2012) Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 79:785\u2013792. https:\/\/doi.org\/10.1212\/WNL.0b013e3182661eb1","journal-title":"Neurology"},{"key":"13338_CR7","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1056\/NEJMoa1805689","volume":"379","author":"MS Maurer","year":"2018","unstructured":"Maurer MS, Schwartz JH, Gundapaneni B et al (2018) Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 379:1007\u20131016. https:\/\/doi.org\/10.1056\/NEJMoa1805689","journal-title":"N Engl J Med"},{"key":"13338_CR8","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, Gonzalez-Duarte A, O\u2019Riordan WD et al (2018) Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 379:11\u201321. https:\/\/doi.org\/10.1056\/NEJMoa1716153","journal-title":"N Engl J Med"},{"key":"13338_CR9","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1056\/NEJMoa1716793","volume":"379","author":"MD Benson","year":"2018","unstructured":"Benson MD, Waddington-Cruz M, Berk JL et al (2018) Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 379:22\u201331. https:\/\/doi.org\/10.1056\/NEJMoa1716793","journal-title":"N Engl J Med"},{"key":"13338_CR10","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13506129.2022.2091985","volume":"30","author":"D Adams","year":"2023","unstructured":"Adams D, Tournev IL, Taylor MS et al (2023) Efficacy and safety of vutrisiran for patients with hereditary transthyretin-mediated amyloidosis with polyneuropathy: a randomized clinical trial. Amyloid 30:1\u20139. https:\/\/doi.org\/10.1080\/13506129.2022.2091985","journal-title":"Amyloid"},{"issue":"Suppl 1","key":"13338_CR11","doi-asserted-by":"publisher","first-page":"61","DOI":"10.3109\/13506129.2012.685665","volume":"19","author":"D Adams","year":"2012","unstructured":"Adams D, Lozeron P, Theaudin M et al (2012) Regional difference and similarity of familial amyloidosis with polyneuropathy in France. Amyloid 19(Suppl 1):61\u201364. https:\/\/doi.org\/10.3109\/13506129.2012.685665","journal-title":"Amyloid"},{"key":"13338_CR12","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1016\/j.jdiacomp.2014.02.013","volume":"28","author":"AG Smith","year":"2014","unstructured":"Smith AG, Lessard M, Reyna S et al (2014) The diagnostic utility of Sudoscan for distal symmetric peripheral neuropathy. J Diabetes Complications 28:511\u2013516. https:\/\/doi.org\/10.1016\/j.jdiacomp.2014.02.013","journal-title":"J Diabetes Complications"},{"key":"13338_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1016\/j.pain.2006.01.041","volume":"123","author":"R Rolke","year":"2006","unstructured":"Rolke R, Baron R, Maier C et al (2006) Quantitative sensory testing in the German research network on neuropathic pain (DFNS): standardized protocol and reference values. Pain 123:231\u2013243. https:\/\/doi.org\/10.1016\/j.pain.2006.01.041","journal-title":"Pain"},{"key":"13338_CR14","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000000820","volume":"5","author":"M Reimer","year":"2020","unstructured":"Reimer M, Forstenpointner J, Hartmann A et al (2020) Sensory bedside testing: a simple stratification approach for sensory phenotyping. Pain Rep 5:e820. https:\/\/doi.org\/10.1097\/PR9.0000000000000820","journal-title":"Pain Rep"},{"key":"13338_CR15","doi-asserted-by":"publisher","DOI":"10.1097\/PR9.0000000000001049","volume":"8","author":"J Sachau","year":"2023","unstructured":"Sachau J, Appel C, Reimer M et al (2023) Test-retest reliability of a simple bedside-quantitative sensory testing battery for chronic neuropathic pain. PAIN Rep 8:e1049. https:\/\/doi.org\/10.1097\/PR9.0000000000001049","journal-title":"PAIN Rep"},{"key":"13338_CR16","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-019-09688-0","author":"D Adams","year":"2020","unstructured":"Adams D, Ando Y, Beir\u00e3o JM et al (2020) Expert consensus recommendations to improve diagnosis of ATTR amyloidosis with polyneuropathy. J Neurol. https:\/\/doi.org\/10.1007\/s00415-019-09688-0","journal-title":"J Neurol"},{"key":"13338_CR17","doi-asserted-by":"publisher","first-page":"2393","DOI":"10.1007\/s00415-012-6619-y","volume":"259","author":"K Arning","year":"2012","unstructured":"Arning K, Naleschinski D, Maag R et al (2012) FabryScan: a screening tool for early detection of Fabry disease. J Neurol 259:2393\u20132400. https:\/\/doi.org\/10.1007\/s00415-012-6619-y","journal-title":"J Neurol"},{"key":"13338_CR18","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1136\/jnnp-2016-315262","volume":"88","author":"A Cortese","year":"2017","unstructured":"Cortese A, Vegezzi E, Lozza A et al (2017) Diagnostic challenges in hereditary transthyretin amyloidosis with polyneuropathy: avoiding misdiagnosis of a treatable hereditary neuropathy. J Neurol Neurosurg Psychiatry 88:457\u2013458. https:\/\/doi.org\/10.1136\/jnnp-2016-315262","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"13338_CR19","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1007\/s00392-019-01467-1","volume":"108","author":"F Aus dem Siepen","year":"2019","unstructured":"Aus dem Siepen F, Hein S, Prestel S et al (2019) Carpal tunnel syndrome and spinal canal stenosis: harbingers of transthyretin amyloid cardiomyopathy? Clin Res Cardiol 108:1324\u20131330. https:\/\/doi.org\/10.1007\/s00392-019-01467-1","journal-title":"Clin Res Cardiol"},{"key":"13338_CR20","doi-asserted-by":"publisher","DOI":"10.3390\/genes12070955","volume":"12","author":"AM Minnella","year":"2021","unstructured":"Minnella AM, Rissotto R, Antoniazzi E et al (2021) Ocular involvement in hereditary amyloidosis. Genes 12:955. https:\/\/doi.org\/10.3390\/genes12070955","journal-title":"Genes"},{"key":"13338_CR21","doi-asserted-by":"publisher","first-page":"3093","DOI":"10.1007\/s00415-013-7124-7","volume":"260","author":"MF Dohrn","year":"2013","unstructured":"Dohrn MF, R\u00f6cken C, De Bleecker JL et al (2013) Diagnostic hallmarks and pitfalls in late-onset progressive transthyretin-related amyloid-neuropathy. J Neurol 260:3093\u20133108. https:\/\/doi.org\/10.1007\/s00415-013-7124-7","journal-title":"J Neurol"},{"key":"13338_CR22","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1212\/01.wnl.0000267338.45673.f4","volume":"69","author":"V Plant\u00e9-Bordeneuve","year":"2007","unstructured":"Plant\u00e9-Bordeneuve V, Ferreira A, Lalu T et al (2007) Diagnostic pitfalls in sporadic transthyretin familial amyloid polyneuropathy (TTR-FAP). Neurology 69:693\u2013698. https:\/\/doi.org\/10.1212\/01.wnl.0000267338.45673.f4","journal-title":"Neurology"},{"key":"13338_CR23","doi-asserted-by":"publisher","first-page":"O13","DOI":"10.1186\/1750-1172-10-S1-O13","volume":"10","author":"A Cortese","year":"2015","unstructured":"Cortese A, Lozza A, Vegezzi E et al (2015) Misdiagnoses of transthyretin amyloidosis: a clinical and electrodiagnostic study. Orphanet J Rare Dis 10:O13. https:\/\/doi.org\/10.1186\/1750-1172-10-S1-O13","journal-title":"Orphanet J Rare Dis"},{"key":"13338_CR24","doi-asserted-by":"publisher","first-page":"e143","DOI":"10.1212\/WNL.0000000000005777","volume":"91","author":"P Lozeron","year":"2018","unstructured":"Lozeron P, Mariani L-L, Dodet P et al (2018) Transthyretin amyloid polyneuropathies mimicking a demyelinating polyneuropathy. Neurology 91:e143\u2013e152. https:\/\/doi.org\/10.1212\/WNL.0000000000005777","journal-title":"Neurology"},{"key":"13338_CR25","first-page":"209","volume-title":"Classification of chronic pain, IASP task force on taxonomy","author":"H Merskey","year":"1994","unstructured":"Merskey H, Bogduk N (1994) Part III: pain terms, a current list with definitions and notes on usage. Classification of chronic pain, IASP task force on taxonomy, 2nd edn. IASP Press, Seattle, pp 209\u2013214","edition":"2"},{"key":"13338_CR26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1097\/j.pain.0000000000000753","volume":"158","author":"R Baron","year":"2017","unstructured":"Baron R, Maier C, Attal N et al (2017) Peripheral neuropathic pain: a mechanism-related organizing principle based on sensory profiles. Pain 158:261\u2013272. https:\/\/doi.org\/10.1097\/j.pain.0000000000000753","journal-title":"Pain"},{"key":"13338_CR27","doi-asserted-by":"publisher","DOI":"10.1002\/brb3.889","volume":"8","author":"F Escolano-Lozano","year":"2018","unstructured":"Escolano-Lozano F, Barreiros AP, Birklein F, Geber C (2018) Transthyretin familial amyloid polyneuropathy (TTR-FAP): parameters for early diagnosis. Brain Behav 8:e00889. https:\/\/doi.org\/10.1002\/brb3.889","journal-title":"Brain Behav"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13338-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-025-13338-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-025-13338-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T10:35:39Z","timestamp":1760524539000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-025-13338-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["13338"],"URL":"https:\/\/doi.org\/10.1007\/s00415-025-13338-z","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"type":"print","value":"0340-5354"},{"type":"electronic","value":"1432-1459"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"19 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 August 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 August 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Juliane Sachau received travel support from Alnylam Pharmaceuticals Inc. and Pfizer, consultant fees from Pfizer Pharma GmbH and AstraZeneca GmbH\u00a0and speaker fees from Gr\u00fcnenthal GmbH, AstraZeneca and Alnylam Germany GmbH. Maike F. Dohrn received financial reimbursement for consulting and advisory board activities and travel support to attend scientific meetings by Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Astra Zeneca PLC, Pfizer Pharmaceuticals, and SOBI GmbH. She further received research funding by Pfizer Pharmaceuticals (ASPIRE 2018). She is a consultant for Applied Therapeutics Inc. Jan Vollert has holds an investigator-initiated grant funded by Viatris. Katrin Hahn received financial reimbursement for consulting, advisory board activities, speaker fees, and\/or contributions to congresses and travel support to attend scientific meetings by Akcea Therapeutics Inc., Alnylam Pharmaceuticals Inc., Amicus, AstraZeneca, GSK, Hormosan, Takeda Pharmaceutical Inc., Pfizer Pharmaceuticals Inc., and Swedish Orphan Biovitrum Inc. and ViiV Healthcare GmbH. KH further received research funding by the foundation Charit\u00e9 (BIH clinical fellow), Alnylam Pharmaceuticals Inc., and Pfizer Pharmaceuticals. Timon Hansen participated in advisory boards and\/or received speaker fees from Alexion, Alnylam, Amgen, BMS, GSK, Janssen, Oncopeptides, Pfizer, and Sanofi. Stefan Gingele reports research support from Alnylam Pharmaceuticals, CSL Behring, Else Kr\u00f6ner Fresenius Foundation, Deutsche Forschungsgemeinschaft, and Hannover Biomedical Research School (HBRS) and consulting and\/or speaker honoraria from Alexion, Alnylam Pharmaceuticals, AstraZeneca, GSK, Pfizer, Merck, and Takeda Pharmaceuticals all outside the submitted work. Elena Enax-Krumova holds an endowed professorship funded by the German Social Accident Insurance (DGUV) since 2019, has received a grant from the Georg Agricola Ruhr foundation and from the Bundesministerium f\u00fcr Wirtschaft und Technologie (grant nr. 50WK2273B) as well as personal fees from Novartis GmbH, Casquar GmbH, OmegaPharma GmbH and painCert GmbH. Ralf Baron reports grant\/research support by EU Projects: \u201cEuropain \u201c (115007). DOLORisk (633491). IMI Paincare (777500), German Federal Ministry of Education and Research (BMBF): Verbundprojekt: Fr\u00fchdetektion von Schmerzchronifizierung (NoChro) (13GW0338C), German Research Network on Neuropathic Pain (01EM0903), Pfizer Pharma GmbH, Sanofi Genzyme GmbH, Gr\u00fcnenthal GmbH, Mundipharma Research GmbH und Co. KG., Alnylam Pharmaceuticals Inc., Zambon GmbH, Bayer AG, and Sanofi Aventis GmbH; speaker fees from Pfizer Pharma GmbH, Sanofi Genzyme GmbH, Gr\u00fcnenthal GmbH, Mundipharma, Lilly GmbH, Desitin Arzneimittel GmbH, Teva GmbH, Bayer AG, MSD GmbH, Seqirus Australia Pty. Ltd, Novartis Pharma GmbH, TAD Pharma GmbH, Gr\u00fcnenthal SA Portugal, Gr\u00fcnenthal Pharma AG Schweiz, Gr\u00fcnenthal B.V. Niederlande, Evapharma, Takeda Pharmaceuticals International AG Schweiz, Ology Medical Education Netherlands, Ever Pharma GmbH, Amicus Therapeutics GmbH, Novo Nordisk Pharma GmbH, Chiesi GmbH, Stada Mena DWC LLC Dubai, Hexal AG, and Viatris; and consultant fees from Pfizer Pharma GmbH, Sanofi Genzyme GmbH, Gr\u00fcnenthal GmbH, Lilly, Novartis Pharma GmbH, Bristol-Myers Squibb, Biogenidec, AstraZeneca GmbH, Daiichi Sankyo, Glenmark Pharmaceuticals S.A., Seqirus Australia Pty. Ltd, Teva Pharmaceuticals Europe Niederlande, Teva GmbH, Genentech, Mundipharma International Ltd. UK, Galapagos NV, Kyowa Kirin GmbH, Vertex Pharmaceuticals Inc., Biotest AG, Celgene GmbH, Desitin Arzneimittel GmbH, Regeneron Pharmaceuticals Inc. USA, Theranexus DSV CEA Frankreich, Abbott Products Operations AG Schweiz, Bayer AG, Gr\u00fcnenthal Pharma AG Schweiz, Akcea Therapeutics Germany GmbH, Asahi Kasei Pharma Corporation, AbbVie Deutschland GmbH & Co. KG, Air Liquide Sante International Frankreich, Alnylam Germany GmbH, Lateral Pharma Pty Ltd, Hexal AG, Angelini, Janssen, SIMR Biotech Pty Ltd Australien, Confo Therapeutics N. V. Belgium, Merz Pharmaceuticals GmbH, Neumentum Inc., F. Hoffmann-La Roche Ltd. Switzerland, AlgoTherapeutix SAS France, Nanobiotix SA France, and AmacaThera Inc. Canada. Lena Rhode, Stefanie Rehm, Manon Sendel, Thomas Skripuletz, and Klarissa St\u00fcrner do not report competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was performed in line with the principles of the Declaration of Helsinki. Approval was granted by the local Ethics Committee of the Medical Faculty, Christian-Albrechts-University Kiel (Date October 22, 2019\/No. 547\/19).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Informed consent was obtained from all individual participants included in this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"608"}}